Using liquid biopsies is minimally invasive, fast and easy to perform and provides an excellent solution to study NRAS, BRAF and EGFR mutations in different cancer types like colorectal cancer and melanoma.
Discover the benefits of the Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay - the easiest and fastest solution to implement liquid biopsy testing in your lab.
The Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay, performed on the Idylla™ System, is a sample-to-result real-time PCR molecular assay for the qualitative detection of 18 mutations in codons 12, 13, 59, 61, 117, 146 of the NRAS gene, 5 mutations in codon 600 of the BRAF gene and 2 mutations in codon 492 of the EGFR gene.
The Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay extracts and amplifies NRAS, BRAF and EGFR circulating tumor DNA (ctDNA) from 1 ml of plasma. Fully automated software interpretation and reporting is also integrated, and provides a result in approx. 110 minutes.
*included in the ctNRAS-BRAF-EGFR-S492R product
Biocartis is recruiting centers for a prospective biomarker study comparing turnaround times of standard of care methods and biomarker testing with Idylla™.
One of the biggest challenges oncology labs face with biomarker testing is the ability to obtain samples of sufficient size and quality. With the Idylla™ system only a minimal amount of sample is needed. For solid biopsies, just one slice of tissue is enough and our plasma-based assays require only 1 ml of plasma.